Experimental HIV Drugs
Experimental HIV Drugs
ICAAC 2008: Long-term Safety of Investigational CCR5 Antagonist Vicriviroc in Treatment-experienced Patients
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 28 October 2008 13:55
- Written by Liz Highleyman
Schering-Plough's investigational CCR5 antagonist vicriviroc has demonstrated potent activity against HIV in laboratory studies and clinical trials of treatment-experienced patients. More than 200 patients received vicriviroc in Phase II trials. In a poster presented at the 48th International Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2008), taking place this week in Washington, DC, researchers described long-term safety data from this population.
AIDS 2008: Investigational Next-generation NNRTI Rilpivirine (TMC278) Demonstrates Potent Antiviral Activity at 96 Weeks in Treatment-naive Patients
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 08 August 2008 13:56
- Written by Liz Highleyman
Tibotec's investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (TMC278) has previously demonstrated good efficacy and tolerability in an international Phase 2b trial of treatment-naive patients through 48 weeks. Investigators presented 96-week follow-up data at the XVII International Conference on AIDS taking place this week in Mexico City.
AIDS 2006: TNX-355 Produces Significant Reduction in HIV Viral Load at 48 Weeks
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 25 August 2006 00:00
- Written by Liz Highleyman
Data on several investigational anti-HIV drug candidates were presented at the XVI International AIDS Conference last week in Toronto, including the latest results from a study of Tanox’s investigational monoclonal antibody, TNX-355. TNX-355 is a recombinant human antibody that binds to domain 2 of the CD4 receptor, thereby blocking the entry of HIV into host cells.
Monoclonal Antibody CCR5 Inhibitor PRO 140 Produces Long-lasting HIV Suppression in Single-dose Study
- Details
- Category: Experimental HIV Drugs
- Published on Friday, 28 September 2007 00:00
- Written by Liz Highleyman
In order to enter human CD4 T-cells, HIV must bind to both the CD4 receptor on the cell surface and 1 of 2 co-receptors, CCR5 or CXCR4. If the virus cannot attach to a co-receptor, it cannot infect new cells. The first oral CCR5 antagonist, maraviroc (Selzentry) was recently approved, and another such agent, vicriviroc, has shown promising results in clinical trials.
Web Design and Development by